Literature DB >> 28991857

Impact of Histological and Endoscopic Remissions on Clinical Recurrence and Recurrence-free Time in Ulcerative Colitis.

Ana Ponte1, Rolando Pinho, Sónia Fernandes, Adélia Rodrigues, Luís Alberto, João Carlos Silva, Joana Silva, Jaime Rodrigues, Mafalda Sousa, Ana Paula Silva, Luísa Proença, Teresa Freitas, Sónia Leite, João Carvalho.   

Abstract

BACKGROUND: Clinical and endoscopic remissions constitute the therapeutic goals in ulcerative colitis (UC). Histological healing is currently not a target in UC. This study aims to determine the impact of the definition of endoscopic remission (Mayo endoscopic subscore [MSe] 0-1) and histological activity in the recurrence of UC and recurrence-free survival time.
METHODS: Patients with UC in clinical remission (partial Mayo score ≤ 1) and endoscopic remission (MSe ≤ 1) who underwent colonoscopy with biopsies between March 2010 and December 2013 were included. The validated Nancy score was used to evaluate histological activity, which considers inactivity if 0 to 1 and activity if 2 to 4. The recurrence-free time was evaluated and recurrence was defined as partial Mayo score ≥ 2, therapy to induce remission, hospitalization, or colectomy. Predictive factors associated with recurrence and time to recurrence were determined.
RESULTS: Sixty patients were included; 58.3% (n = 35) were women, with a mean age of 52.7 years. MSe = 1 was observed in 46.7% (n = 28) and histological activity in 38.3% (n = 23). Clinical recurrence occurred in 31.7% (n = 19) of patients, with a cumulative risk of 17.1%/24.5%/26.7%/40.1% at 12/24/36/48 months, respectively. MSe = 1 (P = 0.02) and histological activity (P = 0.007) were significantly associated with recurrence. Of these, only histological activity (P = 0.03) was an independent predictive factor of recurrence. Patients with MSe = 1 (P = 0.02) and with histological activity (P = 0.01) had a significantly shorter recurrence-free time in univariate analysis. In multivariate analysis, only histological activity (P = 0.02) was an independent predictive factor of lower recurrence-free time.
CONCLUSION: The presence of histological activity represents an independent predictive factor of recurrence and time to recurrence, which was not verified with MSe 0 to 1.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28991857     DOI: 10.1097/MIB.0000000000001275

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  6 in total

Review 1.  Recent advances and emerging therapies in the non-surgical management of ulcerative colitis.

Authors:  Jan Wehkamp; Eduard F Stange
Journal:  F1000Res       Date:  2018-08-07

2.  Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis.

Authors:  Natsuki Ishida; Takahiro Miyazu; Ryosuke Takano; Satoshi Tamura; Shinya Tani; Takuma Kagami; Mihoko Yamade; Yasushi Hamaya; Moriya Iwaizumi; Satoshi Osawa; Takahisa Furuta; Hiroaki Miyajima; Ken Sugimoto
Journal:  BMC Gastroenterol       Date:  2020-04-19       Impact factor: 3.067

3.  Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis.

Authors:  Angelo Viscido; Marco Valvano; Gianpiero Stefanelli; Annalisa Capannolo; Chiara Castellini; Eugenia Onori; Antonio Ciccone; Filippo Vernia; Giovanni Latella
Journal:  BMC Gastroenterol       Date:  2022-03-03       Impact factor: 3.067

4.  PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system.

Authors:  Xianyong Gui; Alina Bazarova; Rocìo Del Amor; Vincenzo Villanacci; Michael Vieth; Gert de Hertogh; Davide Zardo; Tommaso Lorenzo Parigi; Elin Synnøve Røyset; Uday N Shivaji; Melissa Anna Teresa Monica; Giulio Mandelli; Pradeep Bhandari; Silvio Danese; Jose G Ferraz; Bu'Hussain Hayee; Mark Lazarev; Adolfo Parra-Blanco; Luca Pastorelli; Remo Panaccione; Timo Rath; Gian Eugenio Tontini; Ralf Kiesslich; Raf Bisschops; Enrico Grisan; Valery Naranjo; Subrata Ghosh; Marietta Iacucci
Journal:  Gut       Date:  2022-02-16       Impact factor: 23.059

Review 5.  Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?

Authors:  Panu Wetwittayakhlang; Livia Lontai; Lorant Gonczi; Petra A Golovics; Gustavo Drügg Hahn; Talat Bessissow; Peter L Lakatos
Journal:  J Clin Med       Date:  2021-11-26       Impact factor: 4.241

Review 6.  Assessing Severity of Disease in Patients with Ulcerative Colitis.

Authors:  Baldeep Singh Pabla; David Allen Schwartz
Journal:  Gastroenterol Clin North Am       Date:  2020-09-23       Impact factor: 3.806

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.